Autonomix, a medical device company focused on advancing precision nerve-targeted treatments, has announced that the European Patent Office (EPO) has granted Patent No. 3,697,298 (the ‘298 patent), titled “Medical Device with Circuitry for Capturing and Processing Physiological Signals.”

The newly issued patent relates to the use of its proprietary technology to collect and process sensing data for real-time physiological monitoring. The innovation has broad potential applications, including coronary artery/vagal nerve mapping, arterial/renal mapping, bladder/lower urinary tract applications, robotic prosthetics and implants, and central nervous system monitoring for neurotherapy.

Brad Hauser, CEO of Autonomix, said, “By protecting our proprietary circuitry for capturing and processing physiological signals in real time, we continue to strengthen the competitive moat around our technology, which has broad, high-value applications across a number of indications.”

“The ‘298 patent combined with 80 other issued patents positions us to capture opportunities across multiple multi-billion-dollar markets, create diverse revenue streams, and expand our global footprint as we advance toward potential commercialization in the future,” he added.

In particular, the ‘298 patent relates generally to medical devices and methods for acquiring and processing physiological signals and provides a system of distributed signal acquisition modules that enhance signal capture and data integrity during neural mapping procedures. These modules locally capture, amplify, digitize, and transmit physiological signals from sensors arranged along the catheter. Key elements of the technology include, but are not limited to, multiple processing modules paired to one or more sensors, data acquisition logic, analog and digital signal processing circuitry positioned at the source, efficient data transmitting, and a modular microchip design, along with technical advantages that range from miniaturization to precision to noise reduction.

Autonomix’s technology platform utilises a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision-guided sense, treat, and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology.

The company is initially developing the technology for the treatment of pain, with initial trials focused on pancreatic cancer, with the potential to extend to multiple indications, including cardiology, hypertension, and chronic pain management. The technology has not yet been cleared for marketing in the United States.